MCID: GST049
MIFTS: 59

Gastrointestinal System Cancer

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastrointestinal System Cancer

MalaCards integrated aliases for Gastrointestinal System Cancer:

Name: Gastrointestinal System Cancer 12 14
Digestive System Neoplasms 42 69
Gastrointestinal Neoplasms 42 69
Malignant Neoplasm of Gastrointestinal Tract 69
Neoplasm of the Gastrointestinal Tract 29
Gastrointestinal Tract Cancer 12
Cancer of Digestive System 69
Digestive System Cancer 12
Gi Tumor 12

Classifications:



Summaries for Gastrointestinal System Cancer

Disease Ontology : 12 An organ system cancer located in gastrointestinal tract that is manifested in organs of the gastrointestinal system.

MalaCards based summary : Gastrointestinal System Cancer, also known as digestive system neoplasms, is related to gastrointestinal stromal tumor and gastrointestinal neuroendocrine tumor, and has symptoms including signs and symptoms, digestive An important gene associated with Gastrointestinal System Cancer is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs GastroMARK and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and pancreas, and related phenotypes are Decreased viability and homeostasis/metabolism

Related Diseases for Gastrointestinal System Cancer

Diseases in the Gastrointestinal System Cancer family:

Gastrointestinal System Benign Neoplasm

Diseases related to Gastrointestinal System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
id Related Disease Score Top Affiliating Genes
1 gastrointestinal stromal tumor 32.9 AKT1 EGFR KIT TP53 VEGFA
2 gastrointestinal neuroendocrine tumor 32.2 AREG CCND1 CDH1 CEACAM5 CTNNB1 HRAS
3 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 11.3 ADAM17 EGFR
4 breast myoepithelial neoplasm 11.2 CTNNB1 KRAS TP53
5 malignant syringoma 11.2 AFP KRAS TP53
6 adenocarcinoma in situ 11.2 HRAS KRAS TP53
7 severe pre-eclampsia 11.2 EGFR HRAS KRAS
8 urethral obstruction sequence 11.2 AFP CEACAM5
9 malignant skin fibrous histiocytoma 11.2 CEACAM5 HRAS KRAS
10 deep angioma 11.2 CEACAM5 TP53 WWOX
11 congenital mesoblastic nephroma 11.2 EGFR KRAS TP53
12 rectum squamous cell carcinoma 11.2 AKT1 MLH1 TP53
13 spindle epithelial tumor with thymus-like differentiation tumor 11.2 EGFR HRAS KRAS
14 migraine with aura 11.2 HRAS KRAS TP53
15 split-hand/foot malformation 4 11.2 CTNNB1 KRAS TP53
16 advanced sleep phase syndrome 11.2 HRAS KRAS TP53
17 thyroid gland disease 11.2 CTNNB1 MLH1 MSH2
18 pigmented villonodular synovitis 11.2 ADAM17 AFP CEACAM5
19 occupational dermatitis 11.2 EGFR HRAS KRAS
20 primary optic atrophy 11.2 CCND1 TP53 WWOX
21 ossifying fibromyxoid tumor 11.2 HRAS KRAS TP53
22 extragonadal nonseminomatous germ cell tumor 11.2 EGFR KIT TP53
23 stenosis of lacrimal punctum 11.2 CCND1 EGFR HRAS
24 melanocytic nevus syndrome, congenital, somatic 11.2 HRAS MLH1 MSH2
25 chorioangioma 11.2 CCND1 EGFR HRAS
26 gorham's disease 11.2 EGFR HRAS KRAS
27 enamel hypoplasia cataract hydrocephaly 11.2 CTNNB1 KIT TP53
28 tricuspid valve insufficiency 11.2 AFP CEACAM5 KRAS
29 colon signet ring adenocarcinoma 11.2 AFP CTNNB1 TP53
30 sarcoma 11.2 KIT WWOX
31 rheumatic pulmonary valve disease 11.2 CEACAM5 HRAS KRAS
32 sphenoid sinus squamous cell carcinoma 11.2 AFP CEACAM5 KIT
33 appendix adenocarcinoma 11.2 CEACAM5 HRAS KRAS
34 dyserythropoietic anemia and thrombocytopenia 11.2 HRAS KIT KRAS
35 early congenital syphilis 11.2 EGFR HRAS KRAS TLR9
36 sparse hair ptosis mental retardation 11.2 EGFR TP53 VEGFA
37 olfactory neuroblastoma 11.2 EGFR HRAS KRAS TP53
38 clear cell variant infiltrating bladder urothelial carcinoma 11.2 AFP CEACAM5
39 spinal cord dermoid cyst 11.2 CTNNB1 EGFR TP53 WWOX
40 breast adenoid cystic carcinoma 11.2 EGFR HRAS KIT KRAS
41 cecum adenocarcinoma 11.2 EGFR KRAS MLH1 TP53
42 molluscum contagiosum 11.2 EGFR TP53 WWOX
43 pancreatic signet ring cell adenocarcinoma 11.2 CDH1 CTNNB1 TP53
44 sohval soffer syndrome 11.2 CTNNB1 EGFR KRAS
45 pediatric infratentorial ependymoma 11.2 EGFR TP53
46 urethral villous adenoma 11.2 AFP CEACAM5 KIT
47 penis squamous cell carcinoma 11.2 CDH1 CEACAM5 EGFR
48 uterine corpus adenofibroma 11.2 CEACAM5 HRAS KRAS TP53
49 extramedullary plasmacytoma 11.2 CEACAM5 HRAS KRAS TP53
50 hip subluxation 11.2 CCND1 EGFR TP53

Comorbidity relations with Gastrointestinal System Cancer via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Cholestasis Deficiency Anemia
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Gastrointestinal System Cancer:



Diseases related to Gastrointestinal System Cancer

Symptoms & Phenotypes for Gastrointestinal System Cancer

UMLS symptoms related to Gastrointestinal System Cancer:


signs and symptoms, digestive

GenomeRNAi Phenotypes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.16 KRAS EGFR HRAS
2 Decreased viability GR00106-A-0 10.16 KRAS
3 Decreased viability GR00221-A-1 10.16 KRAS AKT1 CDH1 EGFR HRAS KIT
4 Decreased viability GR00221-A-2 10.16 KRAS AKT1 HRAS
5 Decreased viability GR00221-A-3 10.16 AKT1 HRAS
6 Decreased viability GR00221-A-4 10.16 AKT1 EGFR
7 Decreased viability GR00301-A 10.16 KIT KRAS MSH2 CDH1
8 Decreased viability GR00381-A-1 10.16 KRAS
9 Decreased cell migration GR00055-A-1 9.63 ADAM17 AKT1 CTNNB1 EGFR HRAS KRAS
10 Increased cell migration GR00055-A-3 9.02 ADAM17 CTNNB1 EGFR HRAS KRAS

MGI Mouse Phenotypes related to Gastrointestinal System Cancer:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 KIT KRAS MLH1 MSH2 TLR9 TP53
2 endocrine/exocrine gland MP:0005379 10.47 ADAM17 AFP AKT1 AREG CCND1 CDH1
3 cellular MP:0005384 10.46 KRAS MLH1 MSH2 TLR9 TP53 VEGFA
4 mortality/aging MP:0010768 10.44 ADAM17 AFP AKT1 AREG CCND1 CDH1
5 digestive/alimentary MP:0005381 10.42 KIT KRAS MLH1 MSH2 TLR9 TP53
6 cardiovascular system MP:0005385 10.4 VEGFA ADAM17 AKT1 AREG CCND1 CDH1
7 growth/size/body region MP:0005378 10.4 CTNNB1 EGFR HRAS KIT KRAS TP53
8 immune system MP:0005387 10.4 ADAM17 AKT1 AREG CCND1 CDH1 CTNNB1
9 hematopoietic system MP:0005397 10.39 AREG CCND1 CTNNB1 EGFR KIT KRAS
10 integument MP:0010771 10.39 ADAM17 AKT1 AREG CCND1 CDH1 CTNNB1
11 neoplasm MP:0002006 10.32 HRAS KIT KRAS MLH1 MSH2 TP53
12 embryo MP:0005380 10.25 AKT1 CDH1 CTNNB1 EGFR KIT KRAS
13 nervous system MP:0003631 10.23 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
14 craniofacial MP:0005382 10.21 TP53 VEGFA CCND1 CTNNB1 EGFR HRAS
15 liver/biliary system MP:0005370 10.18 AFP AKT1 CTNNB1 EGFR KIT KRAS
16 normal MP:0002873 10.14 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
17 muscle MP:0005369 10.1 TP53 VEGFA ADAM17 AKT1 CTNNB1 EGFR
18 reproductive system MP:0005389 10.1 ADAM17 AFP AKT1 AREG CCND1 CDH1
19 no phenotypic analysis MP:0003012 10.09 TP53 VEGFA WWOX CDH1 CTNNB1 EGFR
20 limbs/digits/tail MP:0005371 10.08 ADAM17 CTNNB1 EGFR KIT KRAS TP53
21 renal/urinary system MP:0005367 9.92 CTNNB1 EGFR HRAS KIT KRAS TLR9
22 respiratory system MP:0005388 9.9 EGFR HRAS KIT KRAS ADAM17 AKT1
23 pigmentation MP:0001186 9.85 ADAM17 CTNNB1 EGFR KIT KRAS TP53
24 skeleton MP:0005390 9.7 ADAM17 AKT1 CCND1 CTNNB1 EGFR HRAS
25 vision/eye MP:0005391 9.32 MLH1 TP53 VEGFA ADAM17 AREG CCND1

Drugs & Therapeutics for Gastrointestinal System Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
GastroMARK 17 FERUMOXSIL Advanced Magnetics May 1996
2
Gleevec 17 46 IMATINIB MESYLATE Novartis May 2001
3
SecreFlo 17 SECRETIN SECRETIN SYNTHETIC PORCINE Repligen April 2002
4
Stivarga 17 46 REGORAFENIB Bayer/ Bayer HealthCare Pharmaceuticals February 2013/ September 2012
5
Sutent 17 46 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Gastrointestinal System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
3 Parecoxib Approved Phase 4 198470-84-7
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 56420-45-2 41867
6
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
7
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
8
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-21-8 3385
9
Tegafur Approved Phase 4,Phase 3,Phase 2,Phase 1 17902-23-7 5386
10
Pravastatin Approved Phase 4,Phase 3 81093-37-0 54687
11
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
12
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
13
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 2216-51-5 16666
14
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 124-94-7 31307
15
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
16
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97682-44-5, 100286-90-6 60838
17
Levoleucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68538-85-2
18
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
19
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
20
Coal tar Approved Phase 4,Phase 3,Phase 1,Phase 2 8007-45-2
21
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 137-58-6 3676
22
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3 142217-69-4 153941
23
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
24
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
25
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
26
Ticlopidine Approved Phase 4,Phase 3 55142-85-3 5472
27
Secretin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 108153-74-8
28
Erythromycin Approved, Vet_approved Phase 4,Phase 2 114-07-8 12560
29
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
30
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
31
Ethiodized oil Approved Phase 4,Phase 3,Phase 2,Phase 1 8008-53-5
32
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
33
Telbivudine Approved, Investigational Phase 4,Phase 1 3424-98-4 159269
34
Zinc Approved Phase 4,Phase 1 7440-66-6 32051 23994
35
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
36
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
37
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6
38
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
39
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
40
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
41
Darbepoetin alfa Approved, Investigational Phase 4,Phase 2,Phase 3 11096-26-7, 209810-58-2
42
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
43
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Early Phase 1 437-38-7 3345
44
Propofol Approved, Investigational, Vet_approved Phase 4,Early Phase 1 2078-54-8 4943
45
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
46
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
47
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2 198153-51-4 5360545
48
Floxuridine Approved Phase 4,Phase 3,Phase 2,Phase 1 50-91-9 5790
49
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
50
Clarithromycin Approved Phase 4,Phase 3,Phase 2 81103-11-9 84029

Interventional clinical trials:

(show top 50) (show all 9060)

id Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4 parecoxib
3 Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery Unknown status NCT00790140 Phase 4
4 Nutritional Supplementation in Patients With no Signs of Malnutrition Unknown status NCT01894828 Phase 4
5 Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients Unknown status NCT00772824 Phase 4
6 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
7 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
8 Outcome Study of Double Bare Stent for Malignant Gastric Outlet Obstruction Unknown status NCT02156505 Phase 4
9 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Unknown status NCT02010762 Phase 4 Vitamin D;Placebo
10 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
11 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
12 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
13 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Unknown status NCT00757640 Phase 4
14 Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms Unknown status NCT01673334 Phase 4
15 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
16 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
17 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
18 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
19 Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
20 Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer Unknown status NCT00874406 Phase 4 tac + folfox4;folfox4
21 Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01972490 Phase 4 avastin+chemotherapy of mFOLFOX6 or FOLFIRI;chemotherapy of mFOLFOX6 or FOLFIRI
22 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
23 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
24 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
25 Preoperative Assessment of Colon Tumor Unknown status NCT00114829 Phase 4
26 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
27 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
28 Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery Unknown status NCT01797770 Phase 4 polyethylene glycol
29 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
30 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
31 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
32 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
33 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
34 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
35 NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery Unknown status NCT01841294 Phase 4 Intravenous Lidocaine;Normal saline infusion
36 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
37 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
38 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
39 OPTIMOX1 in Chinese mCRC Patients Unknown status NCT01023633 Phase 4 Oxaliplatin, LV, 5-FU
40 Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis Unknown status NCT01845467 Phase 4
41 Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy Unknown status NCT02081469 Phase 4
42 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
43 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
44 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
45 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
46 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
47 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
48 Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction Unknown status NCT01514214 Phase 4
49 Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery Completed NCT01700062 Phase 4
50 The Laparotomy Study Completed NCT02140593 Phase 4 Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).;Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.

Search NIH Clinical Center for Gastrointestinal System Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: digestive system neoplasms

Genetic Tests for Gastrointestinal System Cancer

Genetic tests related to Gastrointestinal System Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of the Gastrointestinal Tract 29

Anatomical Context for Gastrointestinal System Cancer

MalaCards organs/tissues related to Gastrointestinal System Cancer:

39
Liver, Colon, Pancreas, Lung, Testes, Breast, T Cells

Publications for Gastrointestinal System Cancer

Articles related to Gastrointestinal System Cancer:

id Title Authors Year
1
The effect of intraoperative hypothermia upon blood transfusion needs and length of stay among gastrointestinal system cancer surgery. ( 28417506 )
2017
2
Perioperative immunonutrition ameliorates the postoperative immune depression in patients with gastrointestinal system cancer (prospective clinical study in 42 patients). ( 15587331 )
2004

Variations for Gastrointestinal System Cancer

Expression for Gastrointestinal System Cancer

Search GEO for disease gene expression data for Gastrointestinal System Cancer.

Pathways for Gastrointestinal System Cancer

Pathways related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 117)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.3 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
2
Show member pathways
14.15 ADAM17 AKT1 CCND1 CDH1 CTNNB1 EGFR
3
Show member pathways
13.92 ADAM17 AKT1 AREG CCL15 CCND1 CDH1
4
Show member pathways
13.65 AKT1 AREG CCL15 CDH1 EGFR HRAS
5
Show member pathways
13.48 AKT1 AREG CCL15 CCND1 EGFR HRAS
6
Show member pathways
13.47 ADAM17 AKT1 CCND1 EGFR HRAS KIT
7
Show member pathways
13.42 AKT1 AREG CCL15 CDH1 CTNNB1 EGFR
8
Show member pathways
13.38 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
9
Show member pathways
13.32 ADAM17 AKT1 AREG CCND1 EGFR HRAS
10
Show member pathways
13.17 AKT1 AREG EGFR HRAS KIT KRAS
11
Show member pathways
13.15 AKT1 AREG EGFR HRAS KIT KRAS
12
Show member pathways
13.1 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
13
Show member pathways
13.02 AKT1 HRAS KRAS MLH1 MSH2 TP53
14
Show member pathways
13.01 ADAM17 AKT1 EGFR HRAS KRAS VEGFA
15
Show member pathways
13.01 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
16
Show member pathways
12.97 AKT1 CTNNB1 HRAS KRAS TP53
17
Show member pathways
12.91 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
18
Show member pathways
12.85 AKT1 EGFR HRAS KIT KRAS TP53
19
Show member pathways
12.84 AKT1 CCND1 CTNNB1 EGFR HRAS KRAS
20 12.81 AKT1 EGFR HRAS KRAS TP53
21
Show member pathways
12.8 AKT1 CDH1 CTNNB1 EGFR HRAS KIT
22
Show member pathways
12.76 AKT1 EGFR HRAS KRAS TP53
23
Show member pathways
12.73 ADAM17 AKT1 CCND1 CTNNB1 HRAS
24 12.73 AKT1 CCND1 CTNNB1 EGFR HRAS KIT
25
Show member pathways
12.65 AKT1 CTNNB1 EGFR HRAS KRAS MSH2
26 12.64 CCND1 EGFR HRAS KRAS TP53 VEGFA
27 12.62 CCND1 MLH1 MSH2 TP53 WWOX
28
Show member pathways
12.62 AKT1 EGFR HRAS KRAS TP53
29
Show member pathways
12.56 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
30 12.54 AKT1 CCND1 CDH1 CTNNB1 TP53
31
Show member pathways
12.54 CCND1 CTNNB1 EGFR HRAS KRAS
32
Show member pathways
12.54 AKT1 CTNNB1 EGFR HRAS KRAS TP53
33
Show member pathways
12.53 AKT1 CTNNB1 EGFR HRAS KRAS
34
Show member pathways
12.52 AKT1 EGFR HRAS KIT KRAS
35
Show member pathways
12.52 AKT1 CTNNB1 HRAS KRAS VEGFA
36 12.51 AKT1 CCND1 CTNNB1 HRAS KRAS TP53
37
Show member pathways
12.48 CTNNB1 HRAS KIT KRAS TP53
38
Show member pathways
12.48 AKT1 EGFR HRAS KRAS VEGFA
39
Show member pathways
12.45 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
40
Show member pathways
12.42 AKT1 CCND1 CTNNB1 HRAS
41
Show member pathways
12.41 AKT1 CCND1 EGFR HRAS
42 12.39 CCND1 HRAS KRAS TP53
43
Show member pathways
12.38 AKT1 EGFR HRAS KRAS
44
Show member pathways
12.37 AKT1 CCND1 EGFR HRAS KRAS TP53
45
Show member pathways
12.37 AKT1 AREG CCND1 EGFR HRAS KRAS
46
Show member pathways
12.35 AKT1 HRAS KRAS TP53 VEGFA
47 12.33 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
48
Show member pathways
12.3 AKT1 AREG EGFR HRAS KRAS VEGFA
49 12.28 AKT1 EGFR HRAS KRAS
50 12.28 AFP AREG CCND1 CDH1 CTNNB1

GO Terms for Gastrointestinal System Cancer

Cellular components related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 ADAM17 AFP AKT1 AREG CCND1 CDH1
2 basolateral plasma membrane GO:0016323 9.46 CEACAM5 CTNNB1 EGFR TLR9
3 catenin complex GO:0016342 9.37 CDH1 CTNNB1
4 flotillin complex GO:0016600 9.32 CDH1 CTNNB1
5 cell-cell junction GO:0005911 9.26 ADAM17 AKT1 CTNNB1 KIT
6 membrane GO:0016020 10.16 ADAM17 AKT1 AREG CCND1 CDH1 CEACAM5

Biological processes related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.93 AKT1 AREG CTNNB1 EGFR HRAS TP53
2 positive regulation of gene expression GO:0010628 9.91 CTNNB1 HRAS KIT KRAS TLR9 TP53
3 positive regulation of cell migration GO:0030335 9.88 ADAM17 EGFR HRAS KIT VEGFA
4 phosphatidylinositol-mediated signaling GO:0048015 9.86 AKT1 EGFR KIT TP53
5 response to estradiol GO:0032355 9.85 AREG CCND1 CTNNB1 EGFR
6 response to glucocorticoid GO:0051384 9.8 AREG CCND1 KRAS
7 Ras protein signal transduction GO:0007265 9.8 HRAS KRAS TP53
8 positive regulation of epithelial cell proliferation GO:0050679 9.79 EGFR HRAS VEGFA
9 cellular response to growth factor stimulus GO:0071363 9.78 AKT1 CTNNB1 EGFR
10 positive regulation of DNA replication GO:0045740 9.75 AREG EGFR HRAS
11 ERBB2 signaling pathway GO:0038128 9.74 EGFR HRAS KRAS
12 positive regulation of protein phosphorylation GO:0001934 9.7 ADAM17 AKT1 CCND1 EGFR HRAS KRAS
13 response to X-ray GO:0010165 9.69 CCND1 MSH2 TP53
14 positive regulation of MAPK cascade GO:0043410 9.67 CTNNB1 HRAS KIT
15 positive regulation of MAP kinase activity GO:0043406 9.65 EGFR HRAS KIT KRAS VEGFA
16 positive regulation of isotype switching to IgG isotypes GO:0048304 9.64 MLH1 MSH2
17 positive regulation of cellular component movement GO:0051272 9.64 ADAM17 VEGFA
18 mitotic G1 DNA damage checkpoint GO:0031571 9.63 CCND1 TP53
19 response to isolation stress GO:0035900 9.62 HRAS KRAS
20 mammary gland alveolus development GO:0060749 9.61 AREG CCND1 VEGFA
21 somatic recombination of immunoglobulin gene segments GO:0016447 9.6 MLH1 MSH2
22 positive regulation of isotype switching to IgA isotypes GO:0048298 9.59 MLH1 MSH2
23 cellular response to indole-3-methanol GO:0071681 9.58 CDH1 CTNNB1
24 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.58 ADAM17 AKT1 EGFR
25 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.52 MLH1 MSH2
26 response to UV-A GO:0070141 9.5 AKT1 CCND1 EGFR
27 epidermal growth factor receptor signaling pathway GO:0007173 9.35 ADAM17 AREG EGFR HRAS KRAS
28 positive regulation of cell proliferation GO:0008284 9.28 ADAM17 AREG CCND1 CTNNB1 EGFR HRAS
29 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.14 AKT1 CTNNB1 EGFR HRAS TLR9 TP53
30 cellular response to DNA damage stimulus GO:0006974 10.04 AKT1 CCND1 MLH1 MSH2 TP53

Molecular functions related to Gastrointestinal System Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein homodimerization activity GO:0042803 9.83 CEACAM5 KIT MSH2 TLR9 VEGFA
2 nucleotide binding GO:0000166 9.72 AKT1 EGFR HRAS KIT KRAS
3 protein phosphatase binding GO:0019903 9.54 CTNNB1 EGFR TP53
4 mismatched DNA binding GO:0030983 9.46 MLH1 MSH2
5 protein kinase binding GO:0019901 9.43 AKT1 CCND1 CTNNB1 EGFR MSH2 TP53
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR KIT
7 nitric-oxide synthase regulator activity GO:0030235 9.26 AKT1 EGFR
8 enzyme binding GO:0019899 9.17 AKT1 CCND1 CTNNB1 EGFR MSH2 TP53
9 guanine/thymine mispair binding GO:0032137 9.16 MLH1 MSH2

Sources for Gastrointestinal System Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....